Merus is a buy with Bizengri approval for NRG1+ cancers, Petosemtamab's potential, and partnership with BHVN for oncology ...

Bezuclastinib's upcoming data in July 2025 could be a game-changer for COGT, offering a lucrative investment opportunity. See ...

Piers Morgan's show devolved into chaos Thursday after he cut the mic on a guest who bizarrely called him "sweetheart" and ...

Option Care gets 75% of its revenues from chronic therapies and 25% from acute treatments, but its growth now looks ...

Xenon has promising Phase 2 data for MDD treatment, robust financials, and a potential in niche markets, despite premium ...

Baltimore County Public Schools Superintendent Myriam Rogers presented a $2.98 billion total operating budget to the school ...

Researchers have discovered a biological mechanism that makes plant roots more welcoming to beneficial soil microbes.

Read here for more on the potential of RCUS's combination therapies for various cancers, with promising Phase 3 trials and ...

Montreal's Haitian community commemorated the lives of more than 220,000 people who died in the 2010 earthquake that struck ...

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...

Financial writer upgrades RCEL stock to Buy due to growth potential, international expansion, and undervaluation ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...